References
- Heijerman H, Westerman E, Conway S, et al. for the consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cystic Fibrosis 2009;8:295–315
- Misra A, Hickey AJ, Rossi C, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011;91:71–81
- Adi H, Young PM, Chan H-K, et al. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci 2010;40:239–47
- Saadane A, Soltys J, Berger M. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-κB activation, cytokine secretion and persistent lung inflammation. J Allergy Clin Immunol 2006;117:1163–639
- Sweeney LG, Wang Z, Loebenberg R, et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305:180–5
- Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 2004;24:3–4
- Petersen EA, Grayson JB, Hersh EM, et al. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. J Antimicrob Chemother 1996;38:819–28
- Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296:12–25
- Zaru M, Mourtas S, Klepetsanis P, et al. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 2007;67:655–66
- Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm 2010;387:187–98
- Wong JP, Yang H, Blasetti KL, et al. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Control Release 2003;92:265–73
- Chono S, Tanino T, Seki T, Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008;127:50–8
- Ellbogen MH, Olsen KM, Gentry-Nielsen MJ, Preheim LC. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 2003;51:83–91
- Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812–17
- Desai TR, Li D, Finlay WH, Wong JP. Determination of surface free energy of interactive dry powder liposome formulations using capillary penetration technique. Colloids Surfaces B Biointerfaces 2001;22:107–13
- Moazeni E, Gilani1 K, Sotoudegan F, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul 2010;27:618–27
- Ruizhi Z, Yingjie D, Wenping S, et al. Determination of ammonium sulfate gradient of blank liposomes by conductivity. J Shenyang Pharm Univ 2008;25:967–70
- Colombo C, John Monhemius A, Plant JA. Platinum, palladium and rhodium release from vehicle exhaust catalysts and road dust exposed to simulated lung fluids. Ecotoxicol Environ Saf 2008;71:722–30
- Son Y-J, McConville JT. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm 2009;382:15–22
- Liu T, Zhao X, Duan J, et al. Influence of material and configuration of microfiltration membranes on preparation of mono-ammonium glycyrrhizinate liposome by membrane extrusion method. Chin Tradit Patent Med 2008;30:185–9
- Blumer JL. Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int J Antimicrob Agents 2005;26:143–7